Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech's website
Kurs & Likviditet
Prenumeration
Kalender
| 2025-05-08 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | Bokslutskommuniké 2024 |
| 2024-11-07 | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | Ordinarie utdelning ACTI 0.00 SEK |
| 2024-05-22 | Årsstämma 2024 |
| 2024-05-08 | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | Bokslutskommuniké 2023 |
| 2023-11-09 | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | Ordinarie utdelning ACTI 0.00 SEK |
| 2023-05-24 | Årsstämma 2023 |
| 2023-05-04 | Kvartalsrapport 2023-Q1 |
| 2023-02-09 | Bokslutskommuniké 2022 |
| 2022-11-03 | Kvartalsrapport 2022-Q3 |
| 2022-08-04 | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2022-05-19 | Årsstämma 2022 |
| 2022-04-21 | Kvartalsrapport 2022-Q1 |
| 2022-02-09 | Bokslutskommuniké 2021 |
| 2021-11-04 | Kvartalsrapport 2021-Q3 |
| 2021-08-05 | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2021-05-19 | Årsstämma 2021 |
| 2021-04-22 | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | Bokslutskommuniké 2020 |
| 2020-11-30 | Extra Bolagsstämma 2020 |
| 2020-11-05 | Kvartalsrapport 2020-Q3 |
| 2020-08-06 | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | Ordinarie utdelning ACTI 0.00 SEK |
| 2020-05-19 | Årsstämma 2020 |
| 2020-04-23 | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | Bokslutskommuniké 2019 |
| 2019-11-14 | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | Ordinarie utdelning ACTI 0.00 SEK |
| 2019-05-23 | Årsstämma 2019 |
| 2019-04-25 | Kvartalsrapport 2019-Q1 |
| 2019-04-04 | Extra Bolagsstämma 2019 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-15 | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | Ordinarie utdelning ACTI 0.00 SEK |
| 2018-05-17 | Årsstämma 2018 |
| 2018-04-26 | Kvartalsrapport 2018-Q1 |
| 2018-03-19 | Extra Bolagsstämma 2018 |
| 2018-02-15 | Bokslutskommuniké 2017 |
| 2017-11-09 | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | Kvartalsrapport 2017-Q2 |
| 2017-06-15 | Årsstämma 2017 |
| 2017-04-27 | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | Bokslutskommuniké 2016 |
| 2016-11-11 | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | Ordinarie utdelning ACTI 0.00 SEK |
| 2016-05-26 | Årsstämma 2016 |
| 2016-04-28 | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | Bokslutskommuniké 2015 |
| 2015-11-06 | Kvartalsrapport 2015-Q3 |
| 2015-06-12 | Ordinarie utdelning ACTI 0.00 SEK |
| 2015-06-11 | Årsstämma 2015 |
| 2015-04-23 | Kvartalsrapport 2015-Q1 |
| 2015-02-11 | Bokslutskommuniké 2014 |
| 2014-12-01 | Extra Bolagsstämma 2014 |
| 2014-11-05 | Kvartalsrapport 2014-Q3 |
| 2014-08-07 | Kvartalsrapport 2015-Q2 |
| 2014-05-16 | Ordinarie utdelning ACTI 0.00 SEK |
| 2014-05-15 | Årsstämma 2014 |
| 2014-04-24 | Kvartalsrapport 2014-Q1 |
| 2014-02-13 | Bokslutskommuniké 2013 |
| 2014-01-16 | 15-7 2014 |
| 2013-11-07 | Kvartalsrapport 2013-Q3 |
| 2013-08-07 | Kvartalsrapport 2013-Q2 |
| 2013-05-16 | Ordinarie utdelning ACTI 0.00 SEK |
| 2013-05-15 | Årsstämma 2013 |
| 2013-04-25 | Kvartalsrapport 2013-Q1 |
| 2013-02-14 | Bokslutskommuniké 2012 |
| 2013-01-10 | 15-6 2013 |
| 2012-11-09 | Kvartalsrapport 2012-Q3 |
| 2012-09-11 | Extra Bolagsstämma 2012 |
| 2012-08-10 | Kvartalsrapport 2012-Q2 |
| 2012-06-14 | Kapitalmarknadsdag 2012 |
| 2012-05-11 | Ordinarie utdelning ACTI 0.00 SEK |
| 2012-05-10 | Årsstämma 2012 |
| 2012-04-26 | Kvartalsrapport 2012-Q1 |
| 2012-02-16 | Bokslutskommuniké 2011 |
| 2012-01-12 | 15-7 2012 |
| 2011-11-03 | Kvartalsrapport 2011-Q3 |
| 2011-08-11 | Kvartalsrapport 2011-Q2 |
| 2011-05-06 | Ordinarie utdelning ACTI 0.00 SEK |
| 2011-05-05 | Årsstämma 2011 |
| 2011-04-28 | Kvartalsrapport 2011-Q1 |
| 2011-02-10 | Bokslutskommuniké 2010 |
| 2010-10-27 | Kvartalsrapport 2010-Q3 |
| 2010-08-11 | Kvartalsrapport 2010-Q2 |
| 2010-05-07 | Ordinarie utdelning ACTI 0.00 SEK |
| 2010-05-06 | Årsstämma 2010 |
| 2010-04-22 | Kvartalsrapport 2010-Q1 |
| 2010-02-11 | Bokslutskommuniké 2009 |
| 2009-11-05 | Kvartalsrapport 2009-Q3 |
| 2009-08-06 | Kvartalsrapport 2009-Q2 |
| 2009-05-08 | Ordinarie utdelning ACTI 0.00 SEK |
| 2009-05-07 | Årsstämma 1 |
| 2009-04-23 | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit, are now available on the company website.
The data were presented in a poster session at the International Ocular Inflammation Society (IOIS) 2023 Meeting in Berlin.
The results presented included safety and tolerability in the phase I randomized, placebo-controlled study with laquinimod eye drops in healthy subjects conducted at the Medical University of Vienna, Department of Clinical Pharmacology. The clinical study (NCT05187403) included 54 healthy subjects who received single doses or multiple doses of laquinimod eye drops in one eye and placebo in the other eye. Laquinimod was demonstrated to be safe and tolerable; no serious adverse events were reported, and ocular assessments did not reveal any tolerability concerns.
In the ocular biodistribution study in rabbit, laquinimod was detected in the cornea and retina/choroid of the rabbit eye following administration of laquinimod eye drops.
A clinical ocular biodistribution study of the eye drop formulation will be conducted at the Byers Eye Institute, Stanford University (Palo Alto, California, USA) with the Principal Investigator Quan Dong Nguyen, MD, MSc, Professor of Ophthalmology, Medicine, and Pediatrics, Stanford University School of Medicine.
Read the poster here.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
About laquinimod
Laquinimod is a first-in-class immunomodulator that promotes immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment. Laquinimod is developed as a new treatment for inflammatory eye disorders in the first step non-infectious uveitis. Laquinimod was previously studied in patients with neurodegenerative and inflammatory diseases, including a phase III randomized study program in multiple sclerosis (MS) patients. The clinical safety and tolerability of laquinimod is well known and preclinical data in disease models support the use of laquinimod for the treatment of severe eye disorders including uveitis and eye disorders with abnormal vascularization.